Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06834074 | Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors(NVL-655-EAP) | available | — | — | Nuvalent Inc.INDUSTRY | 12 | Sep 21, 2026 | clinicaltrials |
| NCT07535359 | Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer | available | — | — | Daiichi SankyoINDUSTRY | 1 | Sep 2, 2026 |
| clinicaltrials |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | available | — | — | Nuvalent Inc.INDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT06761976 | Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 Mutation | available | — | — | BayerINDUSTRY | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07601399 | An EAP Treatment Protocol of Zipalertinib | available | — | — | Taiho Oncology, Inc.INDUSTRY | 0 | Jun 11, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT07310277 | Expanded Access to ABBV-706 | available | — | — | AbbVieINDUSTRY | 0 | Jan 29, 2026 | clinicaltrials |
| NCT06872489 | Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors | available | — | — | Second Life TherapeuticsINDUSTRY | 0 | Jul 23, 2025 | clinicaltrials |
| NCT04146571 | Expanded Access to Ensartinib for Participants With ALK+ NSCLC | available | — | — | Xcovery Holdings, Inc.INDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01317953 | Oral Green Tea Extract for Small Cell Lung Cancer | available | — | — | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 5, 2019 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials